Intellectual property is still seen as a “dirty term” in the EU, the assistant general counsel of pharmaceutical company GlaxoSmithKline has claimed.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
GSK, Harley Davidson, counterfeits, ACTA, WCO, OHIM, GlaxoSmithKline, Sarah Jeffery
